Finally, TRANSCEND-T2D-3 (NCT06297603) will compare retatrutide to placebo over 14 months, in people with inadequately controlled T2D and moderate-or-severe renal impairment on basal insulin
Other important risks include acute pancreatitis, gallbladder disease (including cholelithiasis and cholecystitis), acute kidney injury (particularly in patients experiencing severe gastrointestinal symptoms), hypoglycemia when used with insulin or insulin secretagogues, increased heart rate, diabetic retinopathy complications in patients with diabetes, and suicidal behavior or ideation
O texto alerta que verses no aprovadas de agonistas como semaglutida, tirzepatida e retatrutida no so avaliadas quanto a segurana, eficcia e qualidade, devendo ser evitadas Disponvel em: SURMOUNT3/SURMOUNT4 Trial Results
Therefore, de novo synthesis of GSH is essential for the adaptive response to oxidative stress